# Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

> **NCT00827359** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Renal Cancer

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00827359
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2018-01
- **Final completion:** 2018-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00827359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00827359, "Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00827359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*